Centogene Names Oved Amitay as Chief Business Officer; Increases Focus on Pharma Partnerships
2 November 2018 - - German rare disease genetics specialist Centogene has appointed Oved Amitay as chief business officer, the company said.

With nearly three decades of commercial and development experience, focusing on orphan drugs for patients with rare genetic diseases, Oved joins a leadership team at an inflection point in the company's continued worldwide growth and expansion of collaborations with pharmaceutical partners.

Amitay will have overall responsibility for the company´s pharmaceutical industry programs, including enhancing existing partnerships and establishing new collaborations to facilitate drug development and improve treatment outcomes.

Amitay joins Centogene from Arrett Neuroscience where he held the position of president and chief operating officer, having lead the company's strategy for developing therapies for Rett syndrome.

Prior to that he served as vice president, head of commercial at Alnylam Pharmaceuticals, with a lead role in the organization's transition from a technology- platform focus to a patient-centric drug development and pre-launch enterprise.

Oved had a long tenure at Genzyme Corp. (now Sanofi Genzyme) as vice president, Strategic Development, responsible for programme management, business development, market assessment and business planning for the rare genetic diseases franchise, and as general manager of the Gaucher and MPS business.

He is also a founding advisor of Splisense Therapeutics, Israel. Oved holds a M.Sc., Pharmacology, from Northeastern University, Boston, MA and a B.Sc., Pharmacy, from the Hebrew University, Jerusalem, Israel.